Regular Review
Interferon: therapeutic fact or fiction for the '80s? G M SCOTT,. D A J TYRRELL For many years it had been known that infection with one virus could protect animals against infection with another when, in 1957, Isaacs and Lindenmann1 discovered that medium from tissue cultures challenged with a killed virus could protect other cells against infection. The substances producing these effects are highly active glycoproteins known as interferons. They are released (in conjunction with many other unidentified molecules) from cells infected with virus or exposed to stimuli which mimic virus infection. Interferons probably act on cell membrane receptor sites causing intracellular production of proteins which mainly inhibit the translation of viral m-RNA.
Interferons are relatively species-specific, having maximal activity in cells from the same or closely related species. Furthermore, there are three major types of human interferon with different molecular structures and different physicochemical and antigenic properties. Preparations are arbitrarily defined by comparison with international standard preparations, and one unit of interferon is roughly the amount which reduces viral replication in tissue culture by half.
Sources of interferon-Most clinical studies have been performed using human leucocyte interferon (HuIFNoa). This is made by exposing pooled buffy-coat lymphocytes to a parainfluenza virus which may be inactivated later by acidification. The interferon thus obtained can be purified and concentrated by simple methods to 106-107 units per ml/mg protein for clinical use. 2 The specific activity of pure human leucocyte interferon is about 109 U/mg protein, so clinical material is only about 041% pure. Most of the contaminating protein is probably albumin, but other proteins are present which may be biologically active. Interferon preparations have effects other than the inhibition of viral replication; for example, they inhibit cell growth and multiplication,3 enhance the expression of cell-surface antigens,4 suppress some functions of T and B lymphocytes,5 and enhance the activity of natural killer cells.6 7 Any of these functions may be responsible for the antineoplastic activity8 of interferons under current scrutiny.
Preliminary clinical studies have also been performed with interferon derived from human fibroblasts induced with a synthetic double-stranded RNA (poly I:C). 283:323). Interferon protein produced in this way will have to be separated from the products of bacterial fermentation, and if the carbohydrate component of this interferon is necessary for stability or activity, glycosylation of the molecule will need to be performed after fermentation.
Clinical evaluation of interferon and inducers against infections-Clinical studies with interferon have gone through three phases. Apart from a well-controlled study published in 1962,18 which showed that interferon prepared from monkey kidney cells and given intradermally could protect human skin sites against subsequent vaccination, the early studies (1957-66) using relatively low potency material were either uncontrolled or gave negative results. As difficulties became apparent in manufacturing the large amounts of interferon which appeared to be necessary attention turned to developing and testing a range of interferon inducers. While these were active in studies on animals, they were generally unsuccessful in clinical trials. In the '70s, interest in exogenous interferon was revived by the pioneering effort of Mogensen and Cantell, who used buffy coats from Finnish Red Cross blood units for the mass production of human leucocyte interferon.2 Research with this material and smaller quantities of fibroblast interferon from several groups has been concentrated on infections with herpes viruses, respiratory viruses, and hepatitis B virus. Production limitations have restricted the numbers of clinical trials of interferon: the important ones are summarised in the table. Several poorly controlled or inconclusive studies are excluded from this list, but uncontrolled observations on the effect of interferon in chronic viral infections are included. When well-conducted studies have failed this has generally been attributed to the use of too little interferon-a view confirmed in some diseases by the success of later studies with higher dose schedules.9-22 Nevertheless, an important caveat to these studies (and even more so to the trials in cancer) must be that the preparations given were composed almost entirely of material other than interferon and some of the effects may have been due to impurities.
Study of the interferon system in relation to natural or experimental virus infections has indicated the clinical circumstances in which exogenous interferon could be used. 23 Studies on animals have shown that interferon is most active when given before or with the virus challenge.
Interferon in prophylaxis-Studies of the clinical use of interferon in prophylaxis have given conflicting results. Whereas skin sites can be protected against challenge with vaccinia virus by intradermal inoculations of interferon,18 24 fibroblast interferon given by intramuscular injection three times a week to recipients of renal transplants failed to reduce the frequency of naturally acquired virus infections.25 A more recent study employing daily human leucocyte interferon delayed the onset of cytomegalovirus viraemia in seropositive transplant recipients.26 There was no effect on the reactivation of herpes simplex virus infection nor on the eventual outcome of transplantation in these patients. Reactivation of viral illness may also be expected (though there is no immunosuppression) after surgery to the trigeminal ganglia for tic douloureux, and in one study27 leucocyte interferon given from one day before operation for five days reduced both the frequency and duration of shedding of herpes simplex virus from the oropharynx. Herpes labialis also occurred less often in the patients treated with interferon.
Respiratory diseases-Interferon may be detected in the nasal washings and serum of volunteers infected with influenza.28 29 Peak concentrations of interferon in nasal washings occur around the time of the fall in virus shedding before antibodies are found, suggesting a cause-and-effect relation. Whether or not interferon has a key role in limiting acute virus infections of man is still not clear. In some diseases, such as respiratory syncytial virus infection in children, interferon is rarely detectable in serum or nasal washings,30 virus excretion is protracted, and the fall in the virus titre is associated with a rise in concentration of virusspecific IgA antibody,31 suggesting that resolution of the disease (at least in children in hospital) is not entirely mediated by endogenous interferon.
In another study human leucocyte interferon (14 x 107 U total) given as frequent nasal sprays over four days significantly reduced symptoms and shedding of virus after an experimental challenge with rhinovirus on the second day of treatment with interferon.19 Material of lower potency has proved ineffective.19 32 While interferon,33 like any intranasal liquid,34 has a short half life in the nasal cavity, it needs to be in contact with nasal epithelial cells for a long period to make them resistant to viral infection. 35 It is therefore difficult to understand how, in Russia, nose drops containing a low titre of human leucocyte interferon could cause the degree of protection indicated by the results of a large clinical study on children during an influenza epidemic.36 Experiments are needed to find a method of application of interferon that ensures prolonged contact with the mucosa and to find how late in the course of acute respiratory infection exogenous interferon may be given and still have a clinical effect.
Viral diseases of the eye-Eye-drops containing concentrated human leucocyte interferon (11-31 x 106 U/ml) have been shown to reduce the rate of recurrence of herpetic dendritic ulcers after minimal wiping debridement.37 Dilute eye-drops (6-25 x 104 U/ml) given after thermocautery for herpetic keratitis were no more effective than placebo in accelerating healing or reducing viral shedding.38 More concentrated interferon (106 U/ml), however, was effective in a further similar trial.20 Without local physical treatment, topical interferon given at low concentrations seems an inefficient treatment of herpetic eye disease, but highly concentrated interferon has not yet been evaluated alone. Nevertheless, the combination of high-dose interferon (30 x 
